Overview
- Shares have fallen to levels last seen in 2020 after the latest earnings update.
- DexCom is down about 25% year to date in 2025.
- Third-quarter revenue reported on Oct. 30 was $1.2 billion, up 22% from a year earlier.
- Concerns center on whether GLP-1 weight-loss drugs could reduce long-term need for continuous glucose monitors.
- The stock now trades near 26 times forward earnings, below its historical average.